While pre-emptive rituximab therapy for EBV has substantially reduced the incidence of post-transplant lymphoproliferative disorder, following allogeneic haematopoietic SCT (HSCT), cytomegalovirus (CMV) and adenovirus (ADV) still contribute to significant morbidity and mortality after HSCT. We therefore aimed to identify high-risk children who could benefit from recent advances in virus-specific immunotherapy, define the impact of viral reactivations on survival and estimate the economic burden of pre-emptive antiviral drug therapy. Between 2005 and 2010, prospective monitoring of 291 paediatric HSCT procedures revealed that reactivation of CMV (16%), ADV (15%) and EBV (11%) was frequent during period of CD4 T-cell lymphopenia (p0.15 Â 10 9 L À 1 ; Po0.05). We report significant risk factors for reactivation, most notably the use of serotherapy and development of GVHD (Xgrade II) in the presence of pre-existing infection (ADV) or donor and/or recipient seropositivity (CMV, EBV). Most interestingly, CMV and ADV viraemia were the major independent predictors of mortality (Po0.05). CMV, ADV or EBV viral reactivation caused prolonged hospitalization (Po0.05), accounted for 15% of all mortality and substantially increased the cost of transplantation by Bd22 500 ($34 000). This provides an economic rationale for targeting high-risk HSCT recipients with interventions such as virus-specific cell therapy.
INTRODUCTION
Haematopoietic SCT (HSCT) offers the possibility of curative therapy for haematological, immunological and metabolic conditions. Genoidentical donor transplants (from HLA-matched siblings) can be undertaken using T-replete grafts, whereas nongenoidentical procedures using peripheral blood or bone marrow (BM) stem cell harvests are commonly undertaken with T-cell depletion, even if fully HLA-matched, to prevent GVHD. Conditioning of recipients with myeloablative or reduced intensity chemotherapy is frequently supplemented with serotherapy (alemtuzumab, humanized IgG1 anti-CD52) or antithymocyte globulin to eradicate residual recipient lymphocytes and modulate incoming donor-derived immune cells. This facilitates transplantation across donor-recipient antigen mismatch barriers and reduces the risk of GVHD. 1 While abrogating the risk of GVHD, T-cell depletion increases the risk of viral reactivation and virusrelated disease. [2] [3] [4] In children, three viral pathogens are of particular concern; (i) CMV reactivation has been reported in 40-70% of HSCT recipients who are seropositive or have a seropositive donor. 5 Viraemia can be associated with organ disease, including pneumonitis, hepatitis, colitis and retinitis; (ii) EBV is a major concern, following HSCT, especially during periods of lymphopenia, and historically (before the introduction of Rituximab therapy) 11-26% of transplant recipients developed EBV-related lymphoproliferative disease; [6] [7] [8] (iii) ADV, notably serotypes B and C is particularly problematic in children, with disseminated infection leading to pneumonitis, hepatitis, and colitis and associated with mortality rates of up to 50%. 9, 10 Detection of rising CMV, ADV and EBV viral loads in blood usually leads to pre-emptive intervention with antiviral drug therapy, and when possible, early withdrawal of immunosuppression. Despite prospective monitoring and early intervention with drug therapies, viral disease remains the single most important factor influencing mortality after allogeneic transplantation in children. We monitored immune reconstitution in all children undergoing transplantation over a 5-year period at our centre, and identified patients undergoing procedures associated with a high risk of viral reactivation and defined the impact of viral reactivation on survival following HSCT. Most importantly, for the first time, we provide an estimate of the economic burden of virus reactivation in terms of expenditure on antiviral drugs and extended hospital stay.
METHODS

Patients and transplantation
This was a retrospective study of 278 consecutive children, aged between 0.5 and 197 months who underwent 291 allogeneic HSCT transplant procedures between June 2005 and December 2010. Transplants were defined as myeloablative (TBI X5 Gy single dose or X8 Gy fractionated or BU 48 mg kg À 1 PO or IV equivalent or treosulfan X36 g m À 2 IV), with reduced-intensity (low-dose TBI or BU p8 mg kg À 1 and fludarabine-based regimens) or unconditioned. 11 Serotherapy comprised either alemtuzumab (CAMPATH-1H, humanized IgG1 anti-CD52) or rabbit anti-thymocyte globulin. Most matched sibling grafts were BM derived and undertaken without T-cell depletion (no serotherapy). All unrelated donor grafts (matched or mismatched) were performed with serotherapy irrespective of graft type. Cord blood transplants undertaken after 2006 were performed without serotherapy, as recently described. 12 A small number of children (n ¼ 9) underwent ex-vivo T-cell depletion by CD34 þ stem cell selection for haploidentical transplants and were not included in this study.
Immune reconstitution
Following transplant, serial monitoring of immune reconstitution was undertaken at 1, 2, 3, 6 and 12 months. T-cell recovery was characterized by flow cytometry using FITC or phycoerythrin-labelled Ab against CD3, CD4, CD8, CD19, CD16, CD56.
Monitoring and treatment of viraemia
Taqman PCR-based viral surveillance with a sensitivity of 100 viral copies per mL for CMV, EBV and ADV in whole blood was performed twice weekly until recovery of the CD4 T-cell count 40.3 Â 10 9 L À 1 . All patients had pre-transplant naso-pharyngeal aspirate and stool virology performed. Preexisting ADV infection was defined as detection of ADV from nasopharyngeal aspirate or stool or blood on two consecutive occasions. Significant viraemia was defined as levels breaching a threshold for commencement of antiviral drug therapy as follows:-CMV X10 000 copies per mL; EBV X40 000 copies per mL; ADV X1000 copies per mL in whole blood on two consecutive occasions. 13, 14 Patients with significant viraemia were treated pre-emptively with antiviral drugs as follows:-ganciclovir (5 mg kg À 1 twice a day for 2 weeks, followed by maintenance 5 mg kg
for a week) and/or foscarnet (60 mg kg À 1 thrice a day for 2-3 weeks) for CMV viraemia; rituximab (375 mg m À 2 weekly for 4 weeks) for EBV viraemia; cidofovir (5 mg kg À 1 once every week for 2 weeks, followed by maintenance dose of 5 mg kg À 1 once every 2 weeks with pre-hydration and oral probenecid) for adenoviraemia. Data on inpatient hospital stay and costs of antiviral drug therapy were prospectively stored on electronic hospital and pharmacy databases.
Statistical analysis
Univariate analysis was performed to identify key risk factors associated with viral reactivations using w 2 -test with Yates correction. The covariates analyzed were (i) CMV or EBV seropositivity (donor or recipient) or preexisting adenoviral infection at any site (ii) diagnosis (haematological vs primary immunodeficiency vs metabolic) (iii) stem cell source (BM vs peripheral blood vs cord blood) (iv) 41 Ag HLA mismatch out of 10 (v) conditioning (myeloablative vs reduced intensity vs unconditioned) (vi) serotherapy (vii) acute GVHD and (viii) chronic GVHD. The covariates that had P value o0.2 were included in multivariable analysis using logistic regression in a backward stepwise:likelihood ratio pattern. The time to viral reactivation was analyzed using Mantel-Cox log-rank test. Total inpatient hospital stay in patients with significant viraemia (treated) vs no or lowlevel viraemia (non-treated) patients were compared using Mann-Whitney U test. Medians of CD4 T-cell recovery in patients with significant viraemia (treated) vs no or low-level viraemia (non-treated) patients at various timepoints, following transplantation were compared by paired t-test. Medians and 95% confidence interval of the means of CD4 T-cell recovery are graphically plotted in Figures 1a, b and c.
RESULTS
Transplant characteristics including (1) diagnostic category, (2) HLA matching, (3) stem cell source, (4) use of serotherapy and (5) conditioning regimen are summarized in Table 1 .
Viral reactivation and cellular immune reconstitution PCR-based blood analysis detected significant CMV viraemia in 16% (n ¼ 46), ADV viraemia in 15% (n ¼ 44) and EBV viraemia in 11% (n ¼ 32) of transplants. The median time to onset of ADV and CMV reactivations was 15 and 20 days, respectively, whereas EBV did not reactivate until a median of 74 days after HSCT. The kinetics of CD4 lymphocyte reconstitution were significantly slower in the children with ADV, CMV and EBV reactivation compared to children without viraemia (Po0.05; Figures 1a, b and c). In particular, children developing CMV and ADV reactivation within 2 months of transplantation had median CD4 lymphocyte recovery below 0.15 Â 10 9 L À 1 . Reactivation of EBV within 6 months of transplant was similarly associated with reduced CD4 T-cell recovery.
Risk factors for viral reactivation Univariate analysis was used to determine factors critical in determining viral reactivation (Table 2) . Notably, pre-exisiting viral infection (ADV) or seropositivity (CMV, EBV) and in vivo T-cell depletion using serotherapy were significant risk factors for viral reactivation in blood. CMV viraemia was significantly increased, following PBSC grafting (OR 1.9). ADV and EBV reactivations had additional associations with the use of HLA-mismatched grafts (OR 1.8, 2.2, respectively) and Xgrade II acute GVHD (OR 2.2, 3.6, respectively). Reduced intensity conditioning was found to be a risk factor for EBV reactivation (OR 2.1) but not for CMV or ADV. On multivariable analysis apart from pre-existing viral infection (ADV) or seropositivity (CMV, EBV), the use of PBSC as a graft source remained a significant risk factor for CMV reactivation; whereas for ADV and EBV reactivation, the association with acute GVHD (Xgrade II) remained significant. While 44% of PBSC grafts (n ¼ 39) and 37% of BM grafts (n ¼ 25) undertaken with serotherapy were followed by reactivation of one or more viruses, only 27% of BM grafts (n ¼ 20) and 20% of cord blood transplants (n ¼ 9) reactivated viruses. This is illustrated in Figure 2a Figure 1 . Median CD4 T-cell count (and 95% CI of mean), following HSCT and the development of (a) CMV (b) ADV and (c) EBV viraemia. In first 2 months, CD4 T-cell counts were p0.15 Â 10 9 L À 1 in children with significant CMV and ADV viraemia, whereas in those with significant EBV viraemia, CD4 T-cell counts continued to be p0.15 Â 10 9 L À 1 until 6 months following HSCT. At 1 month, children developing significant CMV and ADV viraemia had significantly lower CD4 T-cell counts compared with those developing nonsignificant (untreated) viraemia or no viraemia. In the case of EBV, CD4 T-cell counts were significantly lower at 6 months. 
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Economic burden of viral reactivation
We assessed economic burden of viral reactivations by calculating the cost of antiviral drugs and excess inpatient hospital stay in children with viral reactivation requiring therapy compared with those with no or low-level viraemia (untreated). Children with viral reactivation remained in hospital for significantly longer periods (127 vs 87 days) (Po0.01). Many of these children had additional transplant-related complications, most notable of which was GVHD. Children with GVHD pgrade II with viral reactivation requiring therapy had extended hospital stay compared with children not requiring antiviral therapy (Po0.05). In children with severe GVHD (Xgrade III), the additional hospital stay was statistically NS, and hence could not be attributed solely to viral reactivation and was not included in our calculations. On the basis of routine inpatient costs of d800 per day ($1200 per day), following HSCT, and adding the cost of antiviral drugs, we estimate viral reactivation costs around d22 500 ($34 000) per patient (Table 3 ). This is likely to be an underestimate of the total cost, as some children will have received intensive care at additional cost, or inpatient care at other hospitals for late reactivations and this data was not captured. Nor have we included additional expenditure associated with radiological tests, endoscopies, ophthalmological examinations and other investigations undertaken in children following viral reactivations.
DISCUSSION
The introduction of prospective monitoring for reactivating viruses at our centre and serial tracking of cellular immune recovery has allowed important risk factors for viral reactivation to be identified. In particular, prolonged CD4 T-cell lymphopenia (p0.15 Â 10 9 L À 1 ) owing to the use of in vivo T-cell depletion with serotherapy and GVHD (Xgrade II) requiring steroids significantly increased the risk of viral reactivation. As expected, reactivation was more likely if the donor was seropositive (measured for CMV and EBV, but not available for ADV) or if the recipient had documented pre-existing ADV infection at any site (Table 2) . CD4 T-cell lymphopenia (p0.15 Â 10 9 L À 1 ) in the first 2 months following HSCT increases the risk of CMV and ADV viraemia, whereas persistence of CD4 lymphopenia beyond 2 months increases the risk of EBV viraemia. CMV viraemia was frequent in children receiving PBSC as a stem cell source, possibly reflecting delayed CMV-specific immune-reconstitution following PBSC Viral reactivation in haematopoietic SCT P Hiwarkar et al grafts. 15 As recently reported, significant EBV viraemia was observed frequently in reduced intensity conditioned transplant reflecting the profound immunosuppression and incomplete ablation of recipient B-cells in this setting. 16 These high-risk groups of patients were more likely to develop blood viraemia and were at risk of virus-related organ disease and mortality. In keeping with the current standards of care, we routinely initiated pre-emptive antiviral drug therapies when significant blood viraemia was detected following HSCT. Rituximab (chimeric moAb against CD20 receptor) therapy has improved the treatment of EBV viraemia and has significantly reduced the incidence of post-transplant lymphoproliferative disorders. 14 However, there have been few recent advances in drug therapy for CMV or ADV, and treatment often requires inpatient admission for i.v infusions and monitoring of blood counts and renal function. Pre-emptive treatment of CMV with ganciclovir has reduced the incidence of CMV-related mortality, however, CMVrelated organ diseases remain a concern. 17 Cidofovir as preemptive therapy for ADV viraemia may help control viral loads, although published data suggests that ADV continues to contribute to post-transplant morbidity and mortality in children. 18, 19 Although only 15% of the deaths in this study were attributed to CMV, ADV or EBV, we found that CMV and ADV reactivations were the two major independent risk factors that increased the risk of treatment-related mortality following HSCT.
Our study further reveals for the first time the extent to which viral reactivation requiring antiviral drug therapy increases the duration of inpatient hospital stay for children. Prolonged hospitalization contributes significantly to the burden of transplant care, and when the cost of antiviral drugs is included, the financial consequences of viral reactivation for the health care provider can be approximated. The calculations are likely to be an underestimate of the true cost, having been on the basis of routine inpatient costs and not including charges attributed to additional investigations or therapy provided at other hospitals. Nor is any data available on the financial impact on family members caring for children in hospital for extended periods. Figure 3 . Probability of survival is significantly decreased in children with (a) significant CMV viraemia and (b) significant ADV viraemia compared with those with nonsignificant (untreated) viraemia or no viraemia. However, (c) in children with significant EBV viraemia, overall survival remained unaffected.
Viral reactivation in haematopoietic SCT P Hiwarkar et al ($34 000) is conservative, the data help to support the case for developing more effective antiviral strategies for high-risk patients. The cost of generating virus-specific T-cells specific for EBV has been estimated to be around $10 000, 20 although a significant investment in infrastructure, logistics and expertise is required to make such therapies readily available. [20] [21] [22] Isolation techniques including magnetic bead cytokine-capture of virus specific T-cells [23] [24] [25] or rapid expansion of peptide Ag-stimulated T-cells 26 may offer cost-effective alternatives in high-risk patients. Targeted cell therapy for children receiving serotherapy to facilitate unrelated BM or peripheral blood grafts, in the presence of either donor and/or recipient seropositivity or pretransplant infection is most likely to provide clinical benefit and a favourable cost:benefit outcome. Hospital stay was extended if children developed viraemia, and could be attributed to viral reactivation in children who also had GVHD pgrade II. The extra stay required for children with GVHD 4grade II was not significantly longer in children with viraemia (Mann-Whitney U test). The cost of additional hospital stay for children with GVHD pII was on the basis of inpatient costs at a tertiary centre in London, UK at d800 per day. The cost of i.v. antiviral drug therapy (rituximab, cidofivir, ribavirin, foscarnet and ganciclovir) for each patient was retrieved from the pharmacy database. Outpatient visitation costs, additional investigations such as radiology, opthalmology or endoscopy and hospitalization or medications prescribed elsewhere were not captured and are not included in the analysis.
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